Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Although there are an increasing number of mental health treatment adaptations for older adults, there are still a number of factors to consider when making these adaptations. Cognitive decline is one such factor that places significant burden on older adults and can interfere with traditional mental health therapies. Engage is a behavioral treatment approach that has shown to be effective in treating late life depression. The investigators are testing the feasibility of Engage as a treatment method for late life depression in older adults with cognitive decline. The objective is to corroborate Engage as an alternative late life depression treatment method for a sub-population of older adults with cognitive decline. Cognitive decline poses a unique mental health treatment barrier that is often over looked in younger populations. With a relatively higher prevalence of cognitive decline in older adulthood, it is imperative that a feasible mental health treatment program that can be effective in the presence of cognitive decline.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Engage Treatment | Experimental | The study is a single-arm study. The single-arm will be implementation of the 9-week protocol of Engage in an older adult population with late-life depression and comorbid executive dysfunction and mild cognitive impairment. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Engage | Behavioral | Engage is a 9-week, behavioral-based, psychotherapy treatment protocol for late-life depression. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Hamilton Depression Rating Scale | Measure of depressive symptoms used to assess changes across treatment from baseline to mid-treatment, to post-treatment, and follow up at 36 weeks post-baseline. Scores range from 0 - 54 with higher scores indicating worse depression. | Assessed at Baseline, Week 6, Week 9, and Week 36 follow-up. |
| Measure | Description | Time Frame |
|---|---|---|
| World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) | Measure of disability and functioning. Scores range from 0 to 100, with higher scores indicating worse disability. | Assessed at Baseline, Week 6, Week 9, and Week 36 follow-up. |
| Behavioral Activation for Depression Scale (BADS) |
| Measure | Description | Time Frame |
|---|---|---|
| Iowa Gambling Task - 2nd Edition | Measure of reward response, decision-making and problem solving. Assess changes in target executive functioning skills across treatment. Produces multiple scores, generally with higher scores indicating better decision making. | Baseline, Week 9, and Week 36 follow-up. |
| Hopkins Verbal Learning Memory Test-Revised |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Brenna R Renn, PhD | Contact | 7028950596 | brenna.renn@unlv.edu | |
| Matthew S Schurr, MA | Contact | 7026957708 | schurm1@unlv.nevada.edu |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Nevada | Recruiting | Las Vegas | Nevada | 89154 | United States |
The data will be used for the current study. Unidentified data will be available for use within Dr. Brenna Renn's TREATment lab for future lab members to use.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D060825 | Cognitive Dysfunction |
| ID | Term |
|---|---|
| D003072 | Cognition Disorders |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C470748 | engage 8200 |
Not provided
Not provided
Not provided
The trial will be a single-arm feasibility trial of Engage for treatment of late-life depression in older adults with comorbid executive/cognitive dysfunction.
Not provided
Not provided
Not provided
Not provided
Measure of behavioral activation (target mechanism). Scores range from 0 to 54, with higher scores indicating more dysfunction. |
| Assessed at Baseline, Week 6, Week 9, and Week 36 follow-up. |
| Social Problem-Solving Inventory Revised-Short Form | measure of problem solving skills. Total scores range from 0 to 100. When all appropriate items are reverse-scored, higher scores indicate better social problem solving functioning. | Assessed at Baseline, Week 6, Week 9, and Week 36 follow-up. |
Measure of memory. Assess potential changes in memory functioning across treatment. Consists of multiple trials and multiple ranges, with higher scores on each trial indicating better memory. |
| Baseline, Week 9, and Week 36 follow-up. |
| Stroop Color-Word Interference Test | Measure of processing speed and response inhibition. Assess changes in target executive functioning skills across treatment. Produces multiple scores across multiple trials and ranges, with higher scores indicating better performance. | Baseline, Week 9, and Week 36 follow-up. |
| Trail Making Test A & B | Measure of processing speed and set-shifting. Assess changes in target executive functioning skills across treatment. Time limited task, with higher time indicating worse performance. | Baseline, Week 9, and Week 36 follow-up. |